UnitedHealth Group (NYSE:UNH) Shares Sold by Checchi Capital Advisers LLC

Checchi Capital Advisers LLC lessened its position in UnitedHealth Group (NYSE:UNH) by 9.1% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 9,231 shares of the healthcare conglomerate’s stock after selling 921 shares during the quarter. Checchi Capital Advisers LLC’s holdings in UnitedHealth Group were worth $1,975,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in UNH. Exane Derivatives lifted its stake in shares of UnitedHealth Group by 15,333.3% in the 4th quarter. Exane Derivatives now owns 463 shares of the healthcare conglomerate’s stock valued at $102,000 after purchasing an additional 460 shares during the period. Aevitas Wealth Management Inc. purchased a new position in shares of UnitedHealth Group in the 4th quarter valued at approximately $102,000. Pathstone Family Office LLC purchased a new position in shares of UnitedHealth Group in the 4th quarter valued at approximately $129,000. Trustcore Financial Services LLC purchased a new position in shares of UnitedHealth Group in the 4th quarter valued at approximately $133,000. Finally, Wealthcare Advisory Partners LLC lifted its stake in shares of UnitedHealth Group by 461.9% in the 3rd quarter. Wealthcare Advisory Partners LLC now owns 826 shares of the healthcare conglomerate’s stock valued at $162,000 after purchasing an additional 679 shares during the period. Institutional investors own 87.11% of the company’s stock.

UnitedHealth Group opened at $242.96 on Friday, MarketBeat.com reports. UnitedHealth Group has a 1-year low of $238.61 and a 1-year high of $240.48. The company has a debt-to-equity ratio of 0.56, a current ratio of 0.71 and a quick ratio of 0.71. The firm has a market capitalization of $232.29 billion, a PE ratio of 24.13, a price-to-earnings-growth ratio of 1.39 and a beta of 0.75.

UnitedHealth Group (NYSE:UNH) last posted its quarterly earnings results on Tuesday, April 17th. The healthcare conglomerate reported $3.04 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.91 by $0.13. UnitedHealth Group had a return on equity of 22.06% and a net margin of 5.41%. The firm had revenue of $55.19 billion during the quarter, compared to analysts’ expectations of $54.90 billion. During the same quarter in the previous year, the business earned $2.37 earnings per share. The company’s revenue was up 13.3% on a year-over-year basis. research analysts anticipate that UnitedHealth Group will post 12.61 EPS for the current fiscal year.

In related news, Director Richard T. Burke sold 10,400 shares of UnitedHealth Group stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $229.87, for a total value of $2,390,648.00. Following the completion of the sale, the director now owns 1,781,657 shares of the company’s stock, valued at $409,549,494.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kenneth Irwin Shine sold 202 shares of UnitedHealth Group stock in a transaction on Thursday, April 19th. The stock was sold at an average price of $237.42, for a total value of $47,958.84. Following the completion of the sale, the director now directly owns 28,948 shares of the company’s stock, valued at approximately $6,872,834.16. The disclosure for this sale can be found here. Insiders sold 72,019 shares of company stock valued at $16,550,733 in the last ninety days. 0.87% of the stock is currently owned by corporate insiders.

UNH has been the subject of a number of research analyst reports. Zacks Investment Research upgraded UnitedHealth Group from a “hold” rating to a “buy” rating and set a $240.00 target price for the company in a research note on Tuesday, April 3rd. Cantor Fitzgerald lifted their price objective on UnitedHealth Group to $300.00 and gave the company an “overweight” rating in a research note on Wednesday, April 18th. Royal Bank of Canada reiterated a “buy” rating on shares of UnitedHealth Group in a research note on Wednesday, April 18th. Barclays started coverage on UnitedHealth Group in a research note on Thursday, March 8th. They set an “overweight” rating and a $265.00 price objective for the company. Finally, Argus lifted their price objective on UnitedHealth Group to $270.00 and gave the company a “buy” rating in a research note on Thursday, January 18th. Two equities research analysts have rated the stock with a hold rating and twenty-six have given a buy rating to the company’s stock. UnitedHealth Group has a consensus rating of “Buy” and a consensus price target of $253.70.

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.

Institutional Ownership by Quarter for UnitedHealth Group (NYSE:UNH)

Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply